|
시장보고서
상품코드
2024542
미세잔존질환 검사 시장 규모 : 기술, 용도, 최종사용자, 지역별(2026-2034년)Minimal Residual Disease Testing Market Size by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2026-2034 |
||||||
세계의 미세잔존질환(MRD) 검사 시장 규모는 2025년에 25억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2034년까지 58억 달러에 달하며, 2026-2034년에 CAGR 9.32%로 성장할 것으로 예측하고 있습니다. 헬스케어 산업의 괄목할 만한 성장, 광범위한 연구개발(R&D) 활동, 급속한 기술 발전이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
미세잔존질환검사는 암 치료 후 환자의 체내에 남아있을 수 있는 소량의 암세포를 검출하고 모니터링하기 위해 사용되는 의료검사입니다. 백혈병, 림프종, 다발성골수종, 일부 고형암 등 다양한 유형의 암 검사에 널리 사용되고 있습니다. MRD 검사에는 유세포분석법, 중합효소연쇄반응(PCR), 차세대염기서열분석(NGS) 등 고감도 기법이 사용됩니다. 이는 암 환자를 모니터링하고 의사가 보다 적절한 치료 결정을 내릴 수 있도록 하는 중요한 의료 검사입니다. MRD 검사는 질병의 재발을 조기에 발견하고, 치료 반응을 보다 정확하게 평가하고, 환자를 식별하여 개별화된 치료 계획 수립을 유도하고, 환자 결과를 개선하고, 맞춤형 치료 계획 수립을 강화하는 데 도움이 됩니다.
미세잔존질환 검사 시장 동향
전 세계에서 암의 유병률이 증가하고 있는 것은 시장 성장을 이끄는 주요 요인 중 하나입니다. MRD 검사는 잔존 암세포를 검출하기 위해 널리 사용되는 고감도 기술로, 질병의 재발을 조기에 감지하고 개인별 맞춤 치료 계획을 수립하는 데 도움이 됩니다. 이에 따라 조혈 조직 및 면역계 세포에서 유래한 혈액암에서 MRD 검사가 진단 및 모니터링 툴로 널리 채택되고 있는 것이 시장 성장을 촉진하고 있습니다. 또한 개인화된 치료 계획과 모니터링을 가능하게 하는 맞춤형 의료에 대한 소비자의 선호도 변화도 시장 성장을 촉진하는 또 다른 요인으로 작용하고 있습니다. 여기에 패턴 식별, 재발 가능성 예측, 진단의 정확성과 유효성 향상, 임상의가 환자 치료에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕는 인공지능(AI)과 MRD 검사의 통합이 시장 성장의 원동력이 되고 있습니다. 또한 질병과 관련된 유전적 변이를 연구하기 위해 데옥시리보핵산(DNA)과 리보핵산(RNA)의 염기서열을 결정하는 NGS 기술의 채택이 증가하고 있는 것도 시장의 전망을 밝게 하고 있습니다. 또한 체내에서 암을 유발할 수 있는 발암물질의 존재를 확인하는 것의 중요성에 대한 사람들의 인식이 높아진 것도 시장 성장을 촉진하고 있습니다. 기타 헬스케어 산업의 괄목할 만한 성장, 광범위한 연구개발(R&D) 활동, MRD 검사 프로그램 부문에 대한 투자 증가 등의 요인도 시장 성장을 촉진할 것으로 예상됩니다.
이 보고서에서 답변하는 주요 질문
- 세계 미세잔존질환 검사 시장은 지금까지 어떤 추세를 보여 왔으며, 향후 수년간 어떤 추세를 보이는가?
- 세계의 미세잔존질환 검사 시장의 시장 촉진요인, 저해요인, 기회요인은 무엇인가?
- 각 촉진요인, 억제요인 및 기회는 세계의 미세 잔존 병변 검사 시장에 어떤 영향을 미치는가?
- 주요 지역 시장은 어디인가?
- 가장 매력적인 미세잔존질환 검사 시장을 형성하고 있는 국가는 어디인가?
- 기술별로 보면 시장 분석은 어떻게 이루어지는가?
- 미세잔존질환 검사 시장에서 가장 매력적인 기술은 무엇인가?
- 용도에 따른 시장 내역은?
- 미세잔존질환 검사 시장에서 가장 매력적인 용도는 무엇인가?
- 최종사용자에 따른 시장 분석은 어떻게 이루어지고 있는가?
- 미세잔존질환 검사 시장에서 가장 매력적인 최종사용자는 누구인가?
- 세계의 미세잔존질환 검사 시장의 경쟁 구조는 어떠한가?
- 세계 미세잔존질환 검사 시장의 주요 진입자/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 기술, 용도, 최종사용자, 지역에 의한 미세잔존질환 검사 시장
제6장 시장 내역 : 기술별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 촉진요인·억제요인·기회
제11장 밸류체인 분석
제12장 Porters Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.05.18The global minimal residual disease (MRD) testing market size reached USD 2.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.8 Billion by 2034, exhibiting a growth rate (CAGR) of 9.32% during 2026-2034. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.
Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.
Minimal Residual Disease (MRD) Testing Market Trends:
The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on technology, application, and end user.
Technology Insights:
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Others
Application Insights:
- Hematological Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
End User Insights:
- Hospitals and Speciality Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.
Key Questions Answered in This Report:
- How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
- What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
- What are the key regional markets?
- Which countries represent the most attractive minimal residual disease (MRD) testing market?
- What is the breakup of the market based on technology?
- Which is the most attractive technology in the minimal residual disease (MRD) testing market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the minimal residual disease (MRD) testing market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the minimal residual disease (MRD) testing market?
- What is the competitive structure of the global minimal residual disease (MRD) testing market?
- Who are the key players/companies in the global minimal residual disease (MRD) testing market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Minimal Residual Disease (MRD) Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Flow Cytometry
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Polymerase Chain Reaction (PCR)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Next Generation Sequencing (NGS)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Application
- 7.1 Hematological Malignancy
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Leukemia
- 7.1.2.2 Lymphoma
- 7.1.3 Market Forecast
- 7.2 Solid Tumors
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Speciality Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostic Laboratories
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Academic and Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Adaptive Biotechnologies Corporation
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Arup Laboratories Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Bio-Rad Laboratories Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Guardant Health
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 Invivoscribe Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Natera Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 NeoGenomics Laboratories Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Sysmex Corporation
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.1 Adaptive Biotechnologies Corporation
